ADHD Across the Lifespan: What Emerging Research Says About Long-Term Health and Ageing

The Society Journal | Research Insight

Abstract

Attention-deficit/hyperactivity disorder (ADHD) has historically been studied most intensively in children and younger adults. That scientific focus is beginning to change.

Emerging longitudinal, epidemiological and neurobiological research is examining ADHD in relation to physical health, premature mortality, cardiovascular disease, cognitive ageing and dementia. Several recent studies have reported concerning associations. A large UK matched-cohort study found substantially lower estimated life expectancy among adults with a recorded ADHD diagnosis. A 2026 Dutch nationwide study identified higher rates of some adverse cardiovascular and cardiorenal outcomes among adults with ADHD who had begun antihypertensive treatment. Meanwhile, a 2026 systematic review and meta-analysis reported an association between previous ADHD diagnosis and all-cause dementia.

None of these findings demonstrate that ADHD itself directly causes cardiovascular disease, dementia or premature death.

They instead raise a more complex question: how might a lifelong neurodevelopmental condition interact with physical health, psychiatric comorbidity, treatment, socioeconomic circumstances, healthcare access and biological ageing over decades?

This Research Insight examines the emerging evidence, its limitations, and why ADHD research increasingly needs to think beyond childhood and across the complete lifespan.

Keywords: ADHD, ageing, cardiovascular health, dementia, mortality, neurodevelopment, adult ADHD, cognitive ageing

Editorial approach

This article is a narrative research synthesis rather than a systematic review.

It prioritises recent peer-reviewed cohort studies, systematic reviews and meta-analyses examining ADHD in adulthood and later life. Particular attention has been given to distinguishing association from causation.

Research reporting increased risk should not be interpreted to mean that a particular health outcome is inevitable for an individual with ADHD.

ADHD does not stop when childhood ends

ADHD is classified as a neurodevelopmental condition because its origins lie in development.

That description has sometimes produced an unintended consequence: ADHD has historically been treated scientifically and culturally as predominantly a condition of childhood.

For many people, it is not.

Symptoms can persist into adulthood, while their expression, impact and interaction with the demands of daily life can change substantially with age. Contemporary research therefore increasingly considers ADHD not simply as a childhood disorder that may occasionally continue, but as a condition whose consequences can extend across decades.

That shift raises questions that ADHD science has historically been less equipped to answer.

What does ADHD look like at 40?

At 60?

At 75?

Does lifelong ADHD interact with physical health?

How should clinicians distinguish longstanding attentional difficulties from age-related cognitive change?

And could the cumulative effects of ADHD-related vulnerability become important for health later in life?

These questions are now moving towards the centre of the research agenda.

A striking finding from UK mortality data

One of the most significant recent studies concerned something much broader than attention or executive function:

life expectancy.

O'Nions and colleagues analysed prospectively collected primary-care data from 792 UK general practices, representing more than 9.5 million people contributing eligible person-time between 2000 and 2019.

The researchers identified:

30,039 adults with a recorded ADHD diagnosis

and

300,390 comparison participants

matched 10:1 by age, sex and primary-care practice.

Their estimated difference in life expectancy was substantial.

Among males with diagnosed ADHD, estimated life expectancy was 73.26 years, compared with 80.03 years among matched comparison males.

Among females with diagnosed ADHD, estimated life expectancy was 75.15 years, compared with 83.79 years among comparison females.

That corresponded to an apparent reduction of:

6.78 years for males

and

8.64 years for females.

These figures are striking.

But they need to be interpreted with considerable care.

ADHD itself was not shown to shorten life

The study does not establish that ADHD directly biologically reduces life expectancy by seven or nine years.

Its authors explicitly caution against that interpretation.

The researchers propose that potentially modifiable factors—including unmet mental and physical healthcare needs, smoking and other health-related factors—may help explain the mortality difference.

There is another major limitation.

Only approximately 0.32% of adults represented in the dataset had a recorded ADHD diagnosis. Based on population prevalence estimates used by the researchers, that represented approximately one in nine of the adults likely to have ADHD.

The diagnosed population may therefore differ considerably from the much larger population of people with ADHD who were not diagnosed.

The study should consequently be understood as describing:

adults with diagnosed ADHD in this UK healthcare dataset

rather than establishing the average life expectancy of every person with ADHD.

That distinction is essential.

Nonetheless, the mortality difference signals a potentially important health inequality requiring explanation.

Why might long-term health outcomes differ?

There is unlikely to be one answer.

ADHD is associated at population level with numerous factors that can influence long-term health, including psychiatric comorbidity, substance-use problems, accidents and injuries, educational and occupational disadvantage, sleep difficulties and difficulties managing aspects of healthcare.

Executive-function difficulties may also matter indirectly.

Managing a long-term condition can require:

remembering medication,

attending appointments,

organising prescriptions,

monitoring symptoms,

planning meals,

maintaining routines,

and following complex treatment instructions.

These tasks rely heavily on executive functions.

This creates a plausible pathway through which ADHD characteristics might affect health management without ADHD itself directly causing another disease.

But plausibility is not proof.

Socioeconomic conditions, co-occurring psychiatric conditions, access to healthcare, medication, sleep, genetics and health behaviours may all act as confounders or mediators.

The research challenge is to separate them.

Cardiovascular health is becoming an important research area

Cardiovascular research provides a useful example of this complexity.

In August 2026, Zhou and colleagues published a nationwide retrospective cohort study in Nature Mental Health using Dutch register data.

The study included 706,414 adults aged 18–90 who were new users of antihypertensive medication and had no previous cardiovascular disease or chronic kidney disease.

Of these participants, 10,689 had ADHD.

Among this specific population, adults with ADHD had a higher adjusted rate of:

heart-failure hospitalisation: HR 1.46, 95% CI 1.12–1.90

and

stroke: HR 1.19, 95% CI 1.03–1.38.

Following the onset of heart failure or chronic kidney disease, some subsequent cardiorenal mortality transitions were also more frequent among participants with ADHD.

This is important evidence.

It is not evidence that ADHD universally produces heart disease.

The population studied matters

The participants in the Zhou study were not a random sample of adults with ADHD.

Every participant had begun antihypertensive medication.

In other words, the study examined a group already receiving treatment related to high blood pressure.

Its question was essentially:

Among adults beginning antihypertensive treatment, do subsequent cardiorenal trajectories differ according to ADHD status?

That is considerably more specific than:

Does ADHD cause cardiovascular disease?

The study was also observational.

Statistical adjustment can account for measured confounders, but observational register data cannot eliminate every unmeasured difference between populations.

The result should therefore be treated as a risk signal warranting further investigation, not evidence of direct causation.

That distinction is particularly important when communicating medical research publicly.

ADHD medication introduces another layer of complexity

Long-term health research must also distinguish between:

the potential effects of ADHD itself

and

the potential effects of its treatment.

These are not the same research question.

A large Swedish nested case-control study by Zhang and colleagues examined 278,027 individuals with ADHD aged 6–64. The final analysis compared 10,388 people who developed cardiovascular disease with 51,672 matched controls.

Longer cumulative ADHD-medication exposure was associated with higher rates of cardiovascular disease, particularly hypertension and arterial disease. For more than five years of cumulative exposure, the adjusted odds ratio for overall cardiovascular disease compared with non-use was 1.23.

Again, the study was observational.

It does not establish that medication necessarily caused those outcomes in individual patients, and the authors emphasised cardiovascular monitoring rather than concluding that treatment should be avoided.

That matters because another large observational study points to a different dimension of treatment.

Treatment may also be associated with reduced mortality

Li and colleagues used Swedish national-register data to emulate a target trial among 148,578 people newly diagnosed with ADHD.

Within three months of diagnosis, 84,204 participants initiated ADHD medication.

During two years of follow-up, medication initiation was associated with a lower rate of all-cause mortality:

HR 0.79

and particularly lower mortality from unnatural causes:

HR 0.75.

The association with natural-cause mortality was not statistically significant.

The researchers found especially notable associations with reduced accidental-poisoning mortality.

This study, too, was observational and cannot provide the certainty of a randomised trial.

But taken together, the cardiovascular and mortality studies illustrate why simplistic narratives are inadequate.

It would be scientifically misleading to conclude either:

ADHD medication is universally harmful to long-term health.

or:

ADHD medication universally protects long-term health.

The evidence instead requires assessment of different outcomes, time periods, medications, individual risk profiles and competing risks.

Treatment can have benefits and risks simultaneously.

ADHD and ageing: a field still in its infancy

One of the clearest research gaps emerges when ADHD populations reach later adulthood.

A 2024 scoping review by Fischer and Nilsen searched the literature concerning people aged 60 years and older with ADHD.

Only 17 studies met their inclusion criteria.

The review concluded that ADHD symptoms can persist into older adulthood but highlighted major gaps involving diagnosis, comorbidities, treatment and the distinction between ADHD and age-related cognitive change.

That is remarkably little evidence for a common neurodevelopmental condition.

The scientific problem is partly historical.

People who are now in their seventies grew up at a time when contemporary ADHD diagnostic concepts were not routinely applied.

Many older adults with longstanding attentional or executive difficulties therefore may never have been diagnosed.

Researchers studying late-life ADHD face a fundamentally different identification problem from researchers studying children today.

What happens to cognition as people with ADHD age?

A systematic review published in the Journal of Attention Disorders examined cognitive research involving adults aged 50 years or older with confirmed ADHD.

Pardo-Palenzuela, Onandia-Hinchado and Diaz-Orueta found only 10 eligible studies:

seven cross-sectional and three longitudinal.

Across those studies, older adults with ADHD generally demonstrated poorer performance in attention and episodic memory compared with younger ADHD groups or healthy older controls.

Findings concerning executive functioning were less consistent.

The authors concluded that considerably more research is required before a distinct late-life cognitive profile can be confidently characterised.

They also highlighted the need for internationally agreed neuropsychological assessment approaches capable of distinguishing ADHD from age-related cognitive conditions.

This distinction becomes increasingly important because some of the symptoms overlap.

ADHD, mild cognitive impairment and dementia can look superficially similar

An older adult who reports:

forgetfulness,

difficulty organising tasks,

distractibility,

poor working memory,

difficulty sustaining attention,

or problems managing daily activities

could potentially be describing longstanding ADHD.

But similar complaints can arise from:

normal ageing,

depression,

sleep disorders,

medication effects,

mild cognitive impairment,

or neurodegenerative disease.

A systematic review of older adults with ADHD notes that this symptom overlap makes late-life differential diagnosis particularly challenging.

Developmental history becomes crucial.

ADHD is neurodevelopmental.

A person whose attentional and organisational difficulties have been present since youth presents a fundamentally different diagnostic picture from somebody developing significant cognitive difficulties for the first time in their seventies.

This becomes especially important as another controversial research question emerges:

Is ADHD associated with dementia risk?

What does the dementia research actually show?

In June 2026, Baiamonte and colleagues published a systematic review and meta-analysis examining previous ADHD diagnosis and dementia.

The review included four cohort studies and one case-control study.

Four cohort studies contributed to the meta-analysis of all-cause dementia, representing more than 3.7 million individuals, including 11,071 people with ADHD.

The pooled hazard ratio for all-cause dementia was:

HR 2.52, 95% CI 1.51–4.22.

At first glance, a figure of 2.52 is dramatic.

It should not be read in isolation.

The uncertainty is substantial

The statistical heterogeneity in the dementia meta-analysis was extremely high:

I² = 87.7%.

That means the contributing studies differed considerably in their effect estimates.

Only four studies contributed to the all-cause dementia meta-analysis.

There was insufficient evidence to conduct comparable meta-analyses for Alzheimer's disease, vascular dementia or Lewy body dementia.

The studies were also observational.

Consequently, this evidence demonstrates an association between recorded ADHD and later dementia diagnoses.

It does not establish that ADHD causes dementia.

Possible explanations include:

shared genetic vulnerability,

cardiovascular or metabolic risk,

psychiatric comorbidity,

substance use,

sleep disturbance,

differences in cognitive reserve,

healthcare utilisation,

diagnostic misclassification,

or other unmeasured factors.

Several may operate simultaneously.

The appropriate conclusion is therefore:

The ADHD–dementia association is important enough to investigate seriously, but not mature enough to support deterministic claims.

Neuroimaging research is beginning to examine older ADHD brains

A preregistered 2026 systematic review by Docteur and colleagues examined neuroimaging studies involving adults aged 35 years and older with clinical ADHD, ADHD symptoms or genetic liability for ADHD.

Only 13 studies met the inclusion criteria.

Eleven were assessed as having low risk of bias.

Across studies, ADHD groups showed differences involving:

fronto-striatal systems,

fronto-parietal systems,

and limbic systems

associated with attention and executive control.

Middle-aged adults with clinical ADHD showed more widespread structural differences, whereas studies involving older adults tended to report differences concentrated more heavily in frontal regions.

Two functional-imaging studies reported frontal hypoactivation together with greater parietal activation, which researchers interpreted as potentially compatible with compensatory recruitment.

But thirteen studies remain an extremely small literature from which to build a theory of ADHD brain ageing.

The review's central conclusion is therefore not that researchers have discovered a characteristic “ageing ADHD brain”.

It is that ADHD-related neural differences may persist into later adulthood and that longitudinal research is now needed to determine how those differences interact with normal and pathological ageing.

Neurodevelopment and neurodegeneration are not the same thing

This point deserves emphasis.

ADHD is a neurodevelopmental condition.

Dementia involves neurodegenerative or other pathological processes affecting cognition later in life.

Finding an epidemiological relationship between the two does not mean ADHD gradually “turns into” dementia.

Nor does evidence of differences in older ADHD brains prove neurodegeneration.

Researchers are instead beginning to ask whether developmental differences might interact with ageing-related processes over decades.

That is a more nuanced hypothesis.

For example, if an individual begins adulthood with differences in executive or attentional networks, does that influence their cognitive reserve later?

Could shared genetic factors contribute both to ADHD-related traits and susceptibility to some late-life conditions?

Could cardiovascular health act as an intermediary?

Could decades of untreated psychiatric or sleep difficulties influence long-term outcomes?

These remain hypotheses requiring longitudinal evidence.

The lifespan model changes the research question

Traditional ADHD research often asks:

How do we reduce symptoms now?

A lifespan perspective asks something broader:

What determines the health trajectory of a person with ADHD over 60 or 70 years?

Those are not interchangeable questions.

Long-term outcomes may be influenced by:

early identification,

educational experiences,

mental healthcare,

physical healthcare,

social relationships,

employment,

sleep,

substance use,

medication,

access to treatment,

economic circumstances,

and co-occurring conditions.

The emerging scientific challenge is therefore to study ADHD within the wider ecology of a person's life.

Avoiding a new form of determinism

Research into mortality, cardiovascular disease and dementia has obvious potential to attract alarming headlines.

That creates a responsibility for careful communication.

The evidence does not mean that a person with ADHD should expect to develop dementia.

It does not mean that cardiovascular disease is inevitable.

And it does not mean that an individual's lifespan can be predicted from an ADHD diagnosis.

Population-level risk estimates describe differences between groups.

They do not determine individual futures.

The distinction is particularly important where modifiable health, healthcare and social factors may contribute substantially to observed outcomes.

Indeed, the UK life-expectancy study's own interpretation was that the disparity was unlikely to arise simply from ADHD itself.

The most productive interpretation of this research is therefore not fatalism.

It is prevention.

What the evidence currently supports

WHAT WE KNOW

ADHD frequently persists beyond childhood and can remain clinically relevant throughout adulthood.

Adults with diagnosed ADHD show poorer average health and mortality outcomes in several large observational datasets.

A UK matched-cohort study found an apparent life-expectancy deficit of approximately 6.8 years among males and 8.6 years among females with diagnosed ADHD, although the diagnosed group represented only a minority of adults likely to have ADHD.

Recent observational evidence also identifies differences in some cardiovascular outcomes among selected adult ADHD populations.

ADHD research in older adults remains remarkably limited.

WHAT THE RESEARCH SUGGESTS

ADHD may need to be considered within a broader lifespan-health framework.

Long-term outcomes could reflect interactions among neurodevelopmental vulnerability, mental health, physical health, treatment, social conditions and healthcare access.

Some research suggests an association between ADHD and later dementia, but the evidence remains small and heterogeneous.

Neuroimaging evidence suggests ADHD-associated neural differences can remain detectable into middle and later adulthood, although the literature remains too limited to establish definitive ageing trajectories.

WHAT WE DO NOT YET KNOW

We do not know whether ADHD independently causes increased risk of dementia.

We do not know precisely why adults with diagnosed ADHD show reduced average life expectancy.

We do not know how much cardiovascular risk is attributable to ADHD characteristics, co-occurring conditions, lifestyle factors, medication, healthcare inequalities or shared biology.

We do not yet understand how ADHD interacts with normal brain ageing over many decades.

And we cannot currently predict an individual's long-term physical or cognitive health outcome from an ADHD diagnosis.

What should be studied next?

Lifelong cohorts

ADHD research needs populations followed over decades.

Short cross-sectional studies cannot explain developmental trajectories, ageing or causation.

Older adults

People over 60 remain significantly under-represented in ADHD research.

This is increasingly difficult to justify as generations diagnosed with ADHD move through adulthood.

Cardiovascular and metabolic health

Researchers need to examine cardiovascular risk while disentangling:

ADHD,

medication exposure,

co-occurring conditions,

health behaviours,

and socioeconomic circumstances.

Dementia

The dementia association requires much larger prospective studies with clear documentation of childhood ADHD history and sufficiently long follow-up.

Treatment across decades

Research needs to investigate not merely whether treatment reduces symptoms, but its broader long-term effects on accidents, mortality, cardiovascular health, functioning and quality of life.

Healthcare access

If difficulties accessing or navigating healthcare contribute to poorer outcomes, this represents a potentially modifiable mechanism rather than an intrinsic consequence of neurodivergence.

Conclusion: ADHD deserves lifespan science

ADHD research has spent decades looking primarily towards childhood.

The emerging evidence suggests that science also needs to look forward.

Into midlife.

Into older adulthood.

And into the health consequences that may accumulate across decades.

Recent studies raise serious questions about mortality, cardiovascular health, cognition and dementia. But those findings should not be converted into simplistic claims that ADHD directly causes premature death or neurodegeneration.

The more interesting scientific question is broader.

What happens when a neurodevelopmental condition interacts with an entire lifetime of biology, healthcare, relationships, treatment, behaviour and social experience?

We do not yet know the answer.

What is becoming increasingly clear is that ADHD cannot be understood completely by studying childhood symptoms alone.

If ADHD exists across the lifespan, ADHD science must do the same.

The Society Research Position

WHAT WE KNOW

ADHD can persist throughout adulthood, and several large observational studies identify important long-term health inequalities among adults with diagnosed ADHD.

WHAT THE RESEARCH SUGGESTS

Long-term ADHD outcomes may arise from interactions among neurodevelopment, physical health, mental health, treatment, healthcare access and social determinants rather than from one direct disease pathway.

WHAT WE DO NOT YET KNOW

Current evidence does not establish that ADHD directly causes cardiovascular disease, dementia or shortened life expectancy.

WHAT SHOULD BE STUDIED NEXT

ADHD research needs large, diverse longitudinal cohorts extending into middle and later adulthood, with simultaneous measurement of neurobiology, physical health, treatment, social conditions and healthcare access.

References

1. O'Nions E, El Baou C, John A, Lewer D, Mandy W, McKechnie DGJ, Petersen I, Stott J. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. British Journal of Psychiatry. 2025;226(5):261–268. doi: 10.1192/bjp.2024.199.

2. Zhou Y, Postmus D, Li S, et al. Long-term cardiorenal illness trajectories after initiation of antihypertensive medications in adults with and without ADHD: a nationwide cohort study. Nature Mental Health. 2026. doi: 10.1038/s44220-026-00718-1.

3. Baiamonte L, Bellante G, Allegra P, et al. Attention Deficit/Hyperactivity Disorder and Risk of Dementia: A Systematic Review and Meta-Analysis. Brain Sciences. 2026;16(6):646. doi: 10.3390/brainsci16060646.

4. Docteur NG, Huston HGP, Krupa AA, Callahan BL. A systematic review of neuroimaging studies of adults aged 35 and older with clinical, symptomatic and genetic risk for attention-deficit/hyperactivity disorder. Dialogues in Clinical Neuroscience. 2026;28(1):259–276. doi: 10.1080/19585969.2026.2700984.

5. Pardo-Palenzuela N, Onandia-Hinchado I, Diaz-Orueta U. Cognitive Profile of ADHD in Older Adults: A Systematic Review. Journal of Attention Disorders. 2026;30(1):152–162. doi: 10.1177/10870547251385758.

6. Fischer S, Nilsen C. ADHD in older adults – a scoping review. Aging & Mental Health. Published online 2024. doi: 10.1080/13607863.2024.2339994.

7. Zhang L, Li L, Andell P, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2024;81(2):178–187. doi: 10.1001/jamapsychiatry.2023.4294.

8. Li L, Zhu N, Zhang L, et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA. 2024;331(10):850–860. doi: 10.1001/jama.2024.0851.

The Society Journal publishes research-led analysis across neurodivergence, science, health, society, education and culture. Research Insights distinguish established evidence from emerging findings and unresolved scientific questions.